An estimated 8 million adults in the U.S. have psoriasis. Last month, the FDA approved Sotyktu (deucravacitinib), the first in a new class of oral medication to treat plaque psoriasis. Will this new product be revolutionary or evolutionary when it comes to plaque psoriasis therapy?
Alzheimer’s drug pipeline news: Biogen Inc. in partnership with Eisai Co. has released encouraging data about their new anti-amyloid monoclonal antibody therapy (lecanemab) currently in clinical trials.
Remarkably, 94% of participants in the supporting study who received Hemgenix were able to discontinue use of intravenous FIX infusions. This is an important consideration since FIX infusion therapy can cost of approximately $500,000–$750,000 per year.
Currently, a significant proportion of the pharmaceutical development pipeline is represented by drugs used to treat rare diseases and, increasingly, gene therapies. For example, 44 drugs in ClearScript’s Brand Pipeline Forecast are used to treat rare diseases and are up for approval in the upcoming six months.